Grace Therapeutics (GRCE) Stock Price, News & Analysis

Company Overview

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.

Key Stats

• Today's Range: $2.83 to $2.97
• 50-Day Range: $1.80 to $3.04
• 52-Week Range: $1.75 to $4.97
• Volume: 33,162 shs
• Average Volume: 57,463 shs
• Market Capitalization: $29.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Buy

Grace Therapeutics Stock Analysis - MarketRank™

Grace Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 476th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Grace Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Grace Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Grace Therapeutics are expected to grow in the coming year, from ($1.06) to ($0.75) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Grace Therapeutics is -2.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Grace Therapeutics is -2.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Grace Therapeutics has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for GRCE.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Grace Therapeutics does not currently pay a dividend.

Dividend Growth

Grace Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for GRCE.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 1.55

News Sentiment

Grace Therapeutics has a news sentiment score of 1.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Grace Therapeutics this week, compared to 1 article on an average week.

Search Interest

2 people have searched for GRCE on MarketBeat in the last 30 days.

MarketBeat Follows

4 people have added Grace Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Grace Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.51% of the stock of Grace Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 6.08% of the stock of Grace Therapeutics is held by institutions.

GRCE Stock Analysis - Frequently Asked Questions

How have GRCE shares performed this year?

Grace Therapeutics' stock was trading at $3.74 on January 1st, 2025. Since then, GRCE stock has decreased by 23.0% and is now trading at $2.88.
View the best growth stocks for 2025 here.

How were Grace Therapeutics' earnings last quarter?

Grace Therapeutics, Inc. (NASDAQ:GRCE) announced its quarterly earnings results on Thursday, February, 13th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.01.

Who are Grace Therapeutics' major shareholders?

Top institutional investors of Grace Therapeutics include Nantahala Capital Management LLC (11.62%), ADAR1 Capital Management LLC (3.39%) and Stonepine Capital Management LLC (2.90%).

How do I buy shares of Grace Therapeutics?

Shares of GRCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 2/13/2025
• Today: 5/28/2025
• Next Earnings (Estimated): 6/20/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GRCE
• Previous Symbol: NASDAQ:GRCE
• CIK: 1444192
• Web: www.acastipharma.com
• Phone: 818-839-4378
• Fax: 45-0687-2272
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $12.00
• High Stock Price Target: $12.00
• Low Stock Price Target: $12.00
• Potential Upside/Downside: +316.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.85 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -20.10%
• Return on Assets: -17.10%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.06
• Quick Ratio: 6.06

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.14 per share
• Price / Book: 0.56

Miscellaneous

• Outstanding Shares: 10,140,000
• Free Float: 8,770,000
• Market Cap: $29.20 million
• Optionable: N/A
• Beta: 0.89